Cantor Fitzgerald Reiterates Overweight on Pliant Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Pliant Therapeutics (NASDAQ:PLRX).
August 08, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Pliant Therapeutics (NASDAQ:PLRX).
An Overweight rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100